PPARA and neoplasm: Recently, a Phase I interventional clinical trial (ClinicalTrials.gov ID NCT03829436) is ongoing to explore the tolerability, safety and tumor inhibiting activity of TPST-1120, selective antagonist of PPARα as monotherapy and with nivolumab, an anti-PD1 antibody against solid tumors including CRC.